Kardigan

View 34 open jobs Website LinkedIn Careers Page

Focus: Kardigan is a Series B cardiovascular-focused biotech company based in South San Francisco developing small molecule therapeutics. The company is advancing a pipeline of cardiovascular drugs targeting hypertension, cardiomyopathy, and aortic valve stenosis.

Cardiovascular

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Open Jobs

34+1 this month

Stable — net +1 jobs in 30d

18 added, 17 removed. Backfill posture.

Should You Work at Kardigan?

AI assessment

Kardigan offers meaningful cardiovascular development experience and near-term catalysts, but recent trial setbacks and early-stage funding status introduce material pipeline and runway risk.

Why Work Here

Active pipeline with three clinical-stage programs in Phase 2/2b-3, providing exposure to mid-stage development decision points and regulatory strategy

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Tonlamarsen

Hypertension

PHASE_2

Clinical Trials (2)

NCT06864104A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)

Phase 2

Help build intelligence for Kardigan

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Heavy hiring in Manufacturing (7 roles) and Clinical Operations (6 roles) signals near-term clinical expansion and potential manufacturing scale-up ahead of potential Phase 3 advancement

Focused cardiovascular strategy with small molecule expertise in a well-defined, high-value therapeutic area

Watch Out For

Recent Phase 2 readout for lead program Tonlamarsen (March 2026) showed mixed results—biomarker hit but no clinical benefit from repeat dosing, creating near-term uncertainty around program viability
Series B stage means limited cash visibility and higher execution risk compared to later-stage companies; no disclosed financials or employee count raises transparency concerns

Generated by Claude from Kardigan's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT07511361Study of Efficacy and Safety of Tonlamarsen in Participants With Acute Severe Hypertension Recently Discharged From the Hospital

Phase 2

Ataciguat

Moderate Aortic Valve Stenosis

PHASE_2_3

Clinical Trials (1)

NCT07001800Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

Phase 2/3

danicamtiv

Symptomatic Genetic Dilated Cardiomyopathy

PHASE_2_3

Clinical Trials (1)

NCT07210723A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Phase 2/3

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Cardiovascular

Publications: 2 in PubMed

Open Roles: 34 active jobs

Therapeutic Area Focus

Cardiovascular

4 pipeline

Marketed

Pipeline

Hiring Trend

Actively Hiring

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial.

Journal of the American College of Cardiology

2025

PMID:41217321

Reduced Expression of MTSS1 Increases Sarcomere Number and Improves Contractility in Select Forms of Monogenic DCM.

JACC. Basic to translational science

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Kardigan

Should You Work at Kardigan?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Kardigan(5)

Open Jobs (34)

Director, Facilities

Director, Clinical Quality Lead

Executive Director, Head of Global Site Management

Director, Clinical Trial Liaison - Northern Midwest: Illinois; Indiana; Michigan; Minnesota; Missouri; Iowa; North Dakota

Executive Director, Data, AI & Collaboration Services

Senior Manager, CMC Quality Operations

Vice President, Clinical Development, Tonlamarsen (TLA)

Director, Clinical Trial Liaison - Mid Atlantic Region (NJ, NY, PA, MA, MD)

Senior Director, Corporate Strategy - Prolaio

Executive Director, Medical Disease Area Lead, DCM/Danicamtiv

Senior Director, IT Business Partner – Medical & Commercial

Senior Manager, IT Business Analyst – Development & Quality

Sr. Director, People and Culture Business Partner - Contract to Hire

Senior Director, Contracts and Transactions Counsel

Director, Contracts and Transactions Counsel

Vice President, Corporate Law and Head of Transactions

Vice President, Product Strategy

Sr. Director, Drug Substance Development

Executive Director, Medical Affairs – Digital Innovation & HEOR (Prolaio)

Senior Manager, Statistical Programming

Associate Director, External Manufacturing

Director, Quality Computer System Assurance (CSA), Data Integrity (DI) & Digital Health Technologies (DHT).

Executive Director, National Director of Field Medical

Executive Director, Clinical Data Management

Director, Medical Science Liaison / Regional Medical Lead – Cardiovascular

Hiring Trend

Research Publications(2)